Biologics News
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM...
KRAZATI® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
CARY, N.C., Dec. 14, 2022 — Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has been selected by Mirati therapeutics as one of two specialty pharmacies in a limited distribution network for KRAZATI® (adagrasib),...
ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson
CARY, N.C., December 12, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs), as the sole specialty...
Biologics by McKesson is now the Exclusive Specialty Pharmacy Provider of XERMELO (telotristat ethyl), an FDA Approved Therapy for Carcinoid Syndrome Diarrhea
CARY, N.C., July 25, 2022 —Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has been selected by TerSera Therapeutics LLC, as the exclusive specialty pharmacy provider for XERMELO® (telotristat ethyl), effective...
VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by CTI BioPharma Corp. as a specialty pharmacy provider for VONJO™ (pacritinib) for the treatment of intermediate or...
PYRUKYND (mitapivat), FDA Approved for Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency, Available Exclusively at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Agios Pharmaceuticals, Inc. as a specialty pharmacy provider for PYRUKYND® (mitapivat) for the treatment of hemolytic...
TARPEYO (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYO™ (budesonide) delayed release capsules...
BESREMi (ropeginterferon alfa-2b-njft), FDA Approved for Treatment of Polycythemia Vera, Available at Biologics by McKesson
CARY, N.C., Dec. 6, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by PharmaEssentia USA Corporation as a specialty pharmacy provider for BESREMi® (ropeginterferon alfa-2b-njft) for the...
Newly Approved LIVTENCITY (maribavir) Now Available at Biologics by McKesson
CARY, N.C., Dec. 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Takeda Pharmaceuticals as a specialty pharmacy provider for LIVTENCITY™ (maribavir) indicated for the treatment of adults...
EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment of EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., NOVEMBER 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Takeda Pharmaceutical Limited Company as a specialty pharmacy provider for EXKIVITY™ (mobocertinib) for the...